BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD0240 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD0240\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06218914-2372@assetmemo.bio
DTSTAMP:20261121T005405Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:AZD0240: Phase 1 readout est. (NCT06218914)
DESCRIPTION:AZD0240\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Phase 1
  Study to Investigate TCRTs KRAS Mutation in Unresectable\, Advanced\, and
 /or Metastatic Solid Tumors\nEstimated primary completion: 30 August 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/azd0240#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06218914
URL:https://assetmemo.bio/drug/azd0240#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
